| Recruiting | Imaging of Solid Tumors Using 18F-TRX NCT06942104 | Rahul Aggarwal | Phase 1 |
| Recruiting | PET [89Zr]DFO-starPEG in Solid Tumors NCT06894745 | Robert Flavell, MD, PhD | Phase 1 |
| Recruiting | A Study of DM002 in Patients With Advanced Solid Tumors NCT06751329 | Xadcera Biopharmaceutical (Suzhou) Co., Ltd. | Phase 1 |
| Recruiting | Trop2-targeted immunoPET Imaging of Solid Tumors NCT06851663 | RenJi Hospital | Phase 2 / Phase 3 |
| Recruiting | A Study of DM005 in Patients With Advanced Solid Tumors NCT06515990 | Doma Biopharmaceutical（Suzhou）Co., Ltd. | Phase 1 |
| Recruiting | A Study of DM001 in Patients With Advanced Solid Tumors NCT06475937 | Xadcera Biopharmaceutical (Suzhou) Co., Ltd. | Phase 1 |
| Recruiting | A Study of Avutometinib for People With Solid Tumor Cancers NCT06104488 | Memorial Sloan Kettering Cancer Center | Phase 1 |
| Recruiting | Thrombin Generation and Prediction of Thromboembolic Events in Oncology Patients at Risk NCT06051214 | Institut Cancerologie de l'Ouest | N/A |
| Active Not Recruiting | A Study of AZD1390 and Stereotactic Body Radiotherapy (SBRT) for People With Metastatic Solid Tumor Cancer NCT05678010 | Memorial Sloan Kettering Cancer Center | Phase 1 |
| Recruiting | Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies NCT05786924 | Institut de Recherches Internationales Servier | Phase 1 / Phase 2 |
| Recruiting | FMT With Nivolumab in Patients With Advanced Solid Cancers Who Have Progressed During Anti-PD-(L)1 Therapy NCT05533983 | Asan Medical Center | N/A |
| Recruiting | PRE-I-SPY Phase I/Ib Oncology Platform Program NCT05868226 | QuantumLeap Healthcare Collaborative | Phase 1 |
| Terminated | Oral AMXT 1501 Dicaprate in Combination With IV DFMO NCT05500508 | Aminex Therapeutics, Inc. | Phase 1 / Phase 2 |
| Terminated | A Study of CF33-hNIS (VAXINIA), an Oncolytic Virus, as Monotherapy or in Combination With Pembrolizumab in Adu NCT05346484 | Imugene Limited | Phase 1 |
| Completed | A Study of Mirdametinib on Its Own or in Combination With Fulvestrant in People With Solid Tumor Cancer NCT05054374 | Memorial Sloan Kettering Cancer Center | Phase 1 / Phase 2 |
| Completed | Psychological Care of Oncology Patients With Post-traumatic Stress in the Context of a COVID-19 NCT04747249 | Centre Francois Baclesse | N/A |
| Terminated | A Study of Romiplostim to Prevent Low Platelet Counts in Children and Young Adults Receiving Chemotherapy for NCT04671901 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Active Not Recruiting | Study of Benralizumab in People With Skin Side Effects Caused by Cancer Therapies NCT04552288 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Recruiting | An Open-Label Study of INV-1120 as a Single Agent and in Combination With Pembrolizumab in Adult Patients With NCT04443088 | Shenzhen Ionova Life Sciences Co., Ltd. | Phase 1 |
| Completed | Geriatric Oncology Screening of Older Patients With Solid Cancers NCT04644874 | Odense University Hospital | — |
| Completed | A Phase 1a/b Study of IK-175 as a Single Agent and in Combination With Nivolumab in Patients With Locally Adva NCT04200963 | Ikena Oncology | Phase 1 |
| Unknown | Study Evaluating GZ17-6.02 in Patients With Advanced Solid Tumors or in Combination With Capecitabine in Metas NCT03775525 | Genzada Pharmaceuticals USA, Inc. | Phase 1 |
| Completed | Influenza Vaccination in Patients Receiving Immune Checkpoint Inhibitor NCT03590808 | Seoul National University Hospital | N/A |
| Completed | Oral AMXT 1501 Dicaprate in Combination With DFMO NCT03536728 | Aminex Therapeutics, Inc. | Phase 1 |
| Unknown | Utilization of Microbiome as Biomarkers and Therapeutics in Immuno-Oncology NCT04264975 | Asan Medical Center | N/A |
| Completed | Prevention of Chest Pain in Chemo-treated Cancer Patients NCT03486340 | Vejle Hospital | N/A |
| Unknown | A Phase 1, Multi-Center, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Mi NCT03129139 | Minneamrita Therapeutics LLC | Phase 1 |
| Unknown | PEN-866 in Patients With Advanced Solid Malignancies NCT03221400 | Tarveda Therapeutics | Phase 1 / Phase 2 |
| Active Not Recruiting | A Trial of Belzutifan (PT2977, MK-6482) Tablets In Patients With Advanced Solid Tumors (MK-6482-001) NCT02974738 | Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Phase 1 |
| Unknown | Study of Blood Immune Cells in Cancer Patients Compared to Controls NCT01312701 | Hadassah Medical Organization | — |